Cash and cash equivalents were approximately $96.7 million as of March 31, 2025.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OKUR:
- OnKure Therapeutics initiated with an Outperform at Evercore ISI
- OnKure Therapeutics price target lowered to $34 from $40 at H.C. Wainwright
- Promising Outlook for OnKure Therapeutics: Strategic Developments and Market Expansion Plans for 2025
- Oppenheimer biotech analyst holds an analyst/industry conference call
- Optimistic Buy Rating for OnKure Therapeutics Driven by Promising OKI-219 Development and Future Prospects